CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Show more

Location: 1111 Main Street, Vancouver, WA, 98660, United States | Website: https://www.cytodyn.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

394.4M

52 Wk Range

$0.10 - $0.49

Previous Close

$0.32

Open

$0.30

Volume

1,059,527

Day Range

$0.30 - $0.33

Enterprise Value

346.8M

Cash

16.4M

Avg Qtr Burn

-1.188M

Insider Ownership

0.55%

Institutional Own.

0.02%

Qtr Updated

02/28/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Leronlimab Details
Non-alcoholic steatohepatitis

Phase 2/3

Update

Phase 2

Data readout

Leronlimab Details
Human immunodeficiency virus

Phase 2

Update

Leronlimab Details
Solid tumor/s, Cancer

Phase 2

Update

Leronlimab Details
Graft-versus-host disease

Failed

Discontinued

Failed

Discontinued